ArticleFrontiers in pharmacology2025
Octreotide combined with pantoprazole in the treatment of elderly patients with peptic ulcer complicated by upper gastrointestinal bleeding.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Upper gastrointestinal bleeding (UGIB) is a serious complication of peptic ulcer (PU), particularly in elderly patients who are at higher risk for adverse outcomes. While pantoprazole is widely used for acid suppression, adding octreotide may enhance hemostatic efficacy by reducing splanchnic blood flow. This study evaluates the efficacy of octreotide combined with pantoprazole in managing UGIB in elderly PU patients. Methods: A retrospective evaluation was conducted from January 2021 to December 2023, including 116 elderly patients (≥60 years) diagnosed with PU and UGIB. Patients were divided into two groups: the control group (n = 60), receiving pantoprazole, and the observation group (n = 56), receiving a combination of octreotide and pantoprazole. Both groups received standard supportive care. Key clinical indicators assessed included hemostasis time, gastric pH, hemoglobin levels, and coagulation parameters, such as prothrombin time (PT), thrombin time (TT), and fibrinogen (Fib) levels. Statistical analysis was performed using SPSS software (Version 27.0), with a significance threshold of p < 0.05. Results: The observation group exhibited a significantly higher effective hemostasis rate (91.07%) compared to the control group (73.33%, p = 0.013). Hemostasis time was shorter in the observation group (27.35 ± 3.52 h) than in the control group (33.04 ± 4.45 h, p < 0.001). Post-treatment gastric pH was significantly higher in the observation group (6.74 ± 1.38) compared to the control group (5.29 ± 1.20, p < 0.001), contributing to improved ulcer healing. Hemoglobin levels and coagulation function (PT, TT, and Fib levels) also showed greater improvement in the observation group, suggesting enhanced recovery and hemostatic stability. Conclusion: The combination of octreotide and pantoprazole is associated with improved hemostatic efficacy in elderly patients with peptic ulcers and upper gastrointestinal bleeding. It is linked to reduced hemostasis time, optimized gastric pH, and improved coagulation function. These findings suggest its potential as a promising approach for managing UGIB in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.